Evaluation of
cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs.
Not exact matches
«We found that pemetrexed
combined with
cisplatin is less toxic, well tolerated, and should be developed for further treatment of cervical cancer,» said gynecologic oncology specialist Dr. David Miller, Professor of Obstetrics and Gynecology and a member of the Harold C. Simmons Cancer Center.
«Given that pemetrexed
combined with
cisplatin may be less toxic than and as active as
cisplatin plus paclitaxel and that it can be
combined with bevacizumab, investigating the comparison of
cisplatin - pemetrexed plus bevacizumab with
cisplatin - paclitaxel plus bevacizumab would be the next appropriate step,» said Dr. Miller, who holds the Amy and Vernon E. Faulconer Distinguished Chair in Medical Science and the Dallas Foundation Chair in Gynecologic Oncology.
Combined niclosamide with
cisplatin inhibits epithelial - mesenchymal transition and tumor growth in
cisplatin - resistant triple - negative breast cancer.
RNA - sequencing dissects the transcriptome of polyploid cancer cells that are resistant to
combined treatments of
cisplatin with paclitaxel and docetaxel.